Bank of America
ENGN icon

Bank of America’s enGene Therapeutics ENGN Stock Holding History

Bank of America’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-647,192
Closed -$4.42M – 7645
2025
Q3 		$4.42M Sell
647,192
-1,358,516
-68% -$6.19M ﹤0.01% 4136
2025
Q2 		$7.3M Hold
2,005,708
– – ﹤0.01% 3520
2025
Q1 		$8.99M Buy
+2,005,708
New +$12.5M ﹤0.01% 3239

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Bank of America's ENGN Position: Q4 2025 in Review

Bank of America sold out of enGene Therapeutics (ENGN) in Q4 2025, closing a stake of 647,192 shares — an estimated $4.42M sold.

Bank of America first reported a position in ENGN in Q1 2025 and held it in 3 quarters. The position peaked at $8.99M in Q1 2025. 58 funds tracked by Wall St. Rank hold ENGN as of Q4 2025.

  • Bank of America reported no remaining enGene Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Bank of America sold 647,192 enGene Therapeutics shares in Q4 2025, an estimated $4.42M.
  • Bank of America first reported a position in enGene Therapeutics in Q1 2025 and held it in 3 quarters.
  • Bank of America's enGene Therapeutics position peaked at $8.99M in Q1 2025.
  • 58 funds tracked by Wall St. Rank held enGene Therapeutics as of Q4 2025.

Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.